Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Ridinilazole · SMT-19969

Small molecule · Inhibitor · developed by Summit Therapeutics

Phase 3 Most advanced trial (none active)

SMMT Developer

1 Registered trials

What is Ridinilazole?

Ridinilazole is an oral narrow-spectrum antibiotic that acts on Clostridioides difficile by inhibiting bacterial cell division, which is bactericidal. It is studied in Clostridioides difficile infection, and it is reported to spare other intestinal bacteria and the bile acid metabolome.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: SMT-19969
Drug type: Small molecule
Mechanism: Inhibitor
Pathways: bacterial cell division, bacterial toxin production, inflammatory response
Therapy area: Infectious disease
Developer: Summit Therapeutics (SMMT)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: 06DX01190R

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03595553	Phase 3	Clostridioides Difficile Infection	Completed	SMMT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Clostridioides Difficile Infection

Sources

NCI Thesaurus

Updated Oct 11, 2026. Something wrong or missing? Report it on the SMMT page.

Follow SMMT, the company behind Ridinilazole

See SMMT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SMMT catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z